Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 14/20 | 0.74 |
| ▸ | CDK1 | P06493 | 13/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.74 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651109 | 0.85 | MAPKAPK2 (1.00) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9920461 | 0.80 | MAPKAPK2 (0.73) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9903995 | 0.78 | PRKD1 (0.67) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9920595 | 0.78 | PRKD1 (1.00) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL29920016 | 0.78 | PRKD1 (1.00) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9919702 | 0.78 | PRKD1 (0.71) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL15472000 | 0.78 | PRKD1 (0.71) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9920615 | 0.78 | PRKD1 (1.00) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9920647 | 0.75 | PRKD1 (0.67) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 | |
| SCHEMBL9905816 | 0.75 | PRKD1 (0.68) | MAPKAPK2CDK1PRKD1PRKD2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840515-B2 | Protein kinase D inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-12 | — | — | US | disclosed |
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2014-02-13 | — | — | US | disclosed |
| WO-2012078859-A2 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | PRKCD, PRKD1, PRKD2 | MAPKAPK2 31/4885CDK1 107/4885PRKD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.